Takeda scores a win for Ninlaro as it aims to pioneer 'switch' maintenance in multiple myeloma

After two setbacks earlier this year, Takeda finally reported good news on Ninlaro, its follow-up to now-off-patent blockbuster Velcade. In a phase 3 trial of the drug as a first-line maintenance treatment in multiple myeloma, patients experienced significant survival benefits.